Cargando…
Targeting the Complement–Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)-induced disease (COVID-19) and Gaucher disease (GD) exhibit upregulation of complement 5a (C5a) and its C5aR1 receptor, and excess synthesis of glycosphingolipids that lead to increased infiltration and activation of innate and adaptive im...
Autores principales: | Trivedi, Vyoma Snehal, Magnusen, Albert Frank, Rani, Reena, Marsili, Luca, Slavotinek, Anne Michele, Prows, Daniel Ray, Hopkin, Robert James, McKay, Mary Ashley, Pandey, Manoj Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695449/ https://www.ncbi.nlm.nih.gov/pubmed/36430817 http://dx.doi.org/10.3390/ijms232214340 |
Ejemplares similares
-
C-X-C Motif Chemokine Ligand 9 and Its CXCR3 Receptor Are the Salt and Pepper for T Cells Trafficking in a Mouse Model of Gaucher Disease
por: Magnusen, Albert Frank, et al.
Publicado: (2021) -
Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease
por: Magnusen, Albert Frank, et al.
Publicado: (2021) -
Sphingolipids: the nexus between Gaucher disease and insulin resistance
por: Fuller, Maria
Publicado: (2010) -
Effects of sphingolipids overload on red blood cell properties in Gaucher disease
por: Dupuis, Lucie, et al.
Publicado: (2020) -
Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses
por: Dubot, Patricia, et al.
Publicado: (2020)